查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1679269

血友病治療市場預測至 2030 年：按血友病類型、治療類型、給藥途徑、最終用戶和地區進行的全球分析

Hemophilia Treatment Market Forecasts to 2030 - Global Analysis By Hemophilia Type (Hemophilia A, Hemophilia B, Hemophilia C, Acquired Hemophilia and Other Hemophilia Types), Treatment Type, Route of Administration, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球血友病治療市場價值為 137 億美元，預計到 2030 年將達到 206 億美元，預測期內的複合年成長率為 7.0%。血友病治療包括治療和預防血友病患者的過度出血，血友病是一種影響血液凝固的遺傳性疾病。恢復正常血液凝固的主要策略是注射因子 VIII（用於治療A型血友病 A）或因子 IX（用於B型血友病）進行替代療法。其他治療方法包括用於長期矯正的基因療法、用於阻止血栓分解的抗纖維蛋白溶解藥物以及用於較輕病例的去氨加壓素 (DDAVP)。預防措施可以幫助減少不定期出血的發生頻率。

血友病患病率不斷上升

血友病患病率的不斷上升正推動市場大幅成長。患者數量的不斷成長推動了對先進治療的需求，例如基因治療、重組凝血因子和長半衰期療法。隨著患者知識的提高和診斷技術的進步，預防保健的採用正在增加。政府計劃和醫療補貼也有助於市場擴張。製藥公司正在投資尖端解決方案以滿足不斷成長的需求，加速市場擴張和可及性。

醫療費用高昂

治療血友病的高費用限制了患者獲得基本治療的機會，阻礙了市場的成長。昂貴的因子替代療法、基因療法和長期治療方法給醫療保健系統和患者帶來了經濟負擔，尤其是在中低收入國家。這導致診斷率降低、治療中斷和對不充分的替代療法的依賴，最終抑制了血友病治療的市場擴張和創新。

擴大醫療基礎設施

醫療保健基礎設施的擴張透過改善人們獲得先進藥品、診斷設施和專科醫生的機會，推動了該行業的發展。增加對診所、醫院和研究設施的投資將改善早期診斷和及時治療，從而減少疾病的發生。官民合作關係、保險覆蓋以及政府舉措都正在促進市場擴張。低溫運輸物流和配送網路的改善也將使凝血因子濃縮物和新型基因療法藥物更廣泛地普及，特別是在開發中國家。

抑制劑開發的風險

抑制劑開發的風險可能會對血友病治療市場產生負面影響，降低標準凝血因子療法的有效性並增加治療的​​複雜性和成本。產生抑制劑的患者需要昂貴的替代療法，例如旁路療法和基因療法，這限制了市場的成長。此外，治療抑制劑需要頻繁監測和專門護理，這會對醫療資源造成壓力。這些挑戰阻礙了患者的治療效果、阻礙了治療的進行並減緩了整體市場的成長。

COVID-19 的影響

COVID-19 疫情導致診斷延遲、就診人數減少、供應鏈受到影響，擾亂了血友病治療市場。由於醫療機構關閉和醫療保健系統緊張，許多患者難以獲得基本藥物。然而，市場對家庭護理和數位健康解決方案的採用有所增加。隨著醫療保健系統的復甦，需求也隨之成長，推動了基因療法和半衰期延長治療的創新，以改善患者的治療效果。

預測期內，基因治療領域預計將佔據最大的市場佔有率

預計基因治療領域將在預測期內佔據最大的市場佔有率，因為腺結合病毒(AAV) 的基因轉移等先進療法能夠實現長期因子生產，從而改善患者的預後和生活品質。市場快速擴張的原因是核准數量的增加、研發支出的增加以及對治療的需求不斷成長。此外，與傳統藥物相比，基因療法由於其終生成本效益高，在血友病治療中變得越來越受歡迎。

預測期內，去氨加壓素細分市場預計將以最高複合年成長率成長

預計去氨加壓素部分在預測期內將呈現最高的成長率。這是因為去氨加壓素促進血管性血友病因子和儲存的第八因子的釋放，從而降低出血風險和更頻繁輸注凝血因子的需要。去氨加壓素易於給藥，有注射劑和鼻內劑型，可提高患者的依從性。需求進一步受到認知度提高、新興市場使用量成長和配方開發的影響，所有這些都對整個血友病治療市場的成長產生了積極影響。

比最大的地區

在預測期內，預計北美將佔據最大的市場佔有率，因為血友病患病率的增加以及有利的報銷政策正在推動市場成長。半衰期延長療法和重組因子製劑等藥物的進步正在改善治療效果。此外，政府舉措和研究資金也支持創新。主要產業參與者和患者權益團體的存在進一步加速了市場擴張。個人化醫療的技術進步也有助於改善治療效果。

複合年成長率最高的地區：

預計預測期內亞太地區將呈現最高的複合年成長率。這是因為醫療保健很容易獲得，特別是在中國和印度等開發中國家。人們正在使用預防性治療而不是按需治療，基因和因子替代療法的問題越來越少，需求也越來越大。此外，製藥公司和醫療保健提供者之間的合作正在提高治療方法的可用性，並且由於患有遺傳性出血問題的老齡人口不斷增加，市場也在不斷擴大。

免費客製化服務：

訂閱此報告的客戶可享有以下免費自訂選項之一：

  • 公司簡介
    • 全面分析其他市場參與者（最多 3 家公司）
    • 主要企業的 SWOT 分析（最多 3 家公司）
  • 地理細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭性基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第 2 章 前言

  • 概述
  • 相關利益者
  • 研究範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二手研究資料資訊來源
    • 先決條件

第3章 市場走勢分析

  • 驅動程式
  • 限制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第 4 章 波特五力分析

  • 供應商的議價能力
  • 買家的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

第 5 章 全球血友病治療市場（依血友病類型分類）

  • A型血友病A
  • B型血友病
  • 血友病C
  • 後天性血友病
  • 其他類型的血友病

6. 全球血友病治療市場依治療類型分類

  • 因子替代治療
    • 重組Ⅷ因子
    • 重組 IX 因子
    • 血漿衍生產品
    • 半衰期延長因子濃縮物
  • 去氨加壓素
  • 基因治療
  • 抗纖維溶解劑
  • 其他類型的治療

7. 全球血友病治療市場依給藥途徑分類

  • 靜脈注射 (IV)
  • 皮下
  • 肌肉注射（IM）

8. 全球血友病治療市場（依最終用戶分類）

  • 醫院
  • 血友病治療中心
  • 居家護理
  • 門診手術中心
  • 其他最終用戶

9. 全球血友病治療市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第10章 主要進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • Takeda Pharmaceutical Company Limited
  • Octapharma AG.
  • CSL Behring
  • Medtronic
  • Pfizer, Inc.
  • Novo Nordisk A/S.
  • Bayer AG
  • Allergan
  • BioMarin
  • Aptevo Therapeutics
  • Spark Therapeutics, Inc.
  • AscellaHealth
  • Sanofi
  • Baxter International
  • F. Hoffmann La-Roche Ltd.
Product Code: SMRC28852

According to Stratistics MRC, the Global Hemophilia Treatment Market is accounted for $13.7 billion in 2024 and is expected to reach $20.6 billion by 2030 growing at a CAGR of 7.0% during the forecast period. Hemophilia treatment entails treating and preventing excessive bleeding in people who have hemophilia, a genetic illness that affects blood clotting. In order to restore normal clotting, the main strategy is replacement therapy, which involves injecting clotting factors VIII (for hemophilia A) or IX (for hemophilia B). Additional therapies include gene therapy for long-term correction, antifibrinolytic medications to stop clot breakdown, and desmopressin (DDAVP) for mild cases. Prophylactic (preventive) measures aid in lowering the frequency of unplanned bleeding episodes.

Market Dynamics:

Driver:

Increasing Prevalence of Hemophilia

The rising prevalence of hemophilia is fueling significant growth in the market. The need for advanced therapeutics, including as gene therapy, recombinant clotting factors, and longer half-life treatments, is being driven by an increase in the number of patients. Prophylactic treatment adoption is increasing as a result of increased patient knowledge and better diagnosis. Market expansion is also being aided by government programs and healthcare subsidies. Pharmaceutical firms are making investments in cutting-edge solutions to satisfy rising demand, which is speeding up market expansion and accessibility.

Restraint:

High Treatment Costs

The high cost of hemophilia treatment significantly hinders market growth by limiting patient access to essential therapies. Expensive clotting factor replacement therapies, gene therapies, and prolonged treatment regimens impose a financial burden on healthcare systems and patients, particularly in low- and middle-income countries. This leads to reduced diagnosis rates, treatment discontinuation, and reliance on inadequate alternatives, ultimately restraining market expansion and innovation in hemophilia care.

Opportunity:

Expanding Healthcare Infrastructure

Expanding healthcare infrastructure boosts the industry by increasing access to sophisticated medicines, diagnostic facilities, and specialist care. Investing more in clinics, hospitals, and research facilities improves early diagnosis and prompt treatment, which lowers problems. Public-private partnerships, insurance coverage, and government initiatives all contribute to market expansion. Better cold chain logistics and distribution networks also make clotting factor medicines and new gene therapies more widely available, especially in developing nations, which eventually improves patient outcomes and propels market expansion.

Threat:

Risk of Inhibitor Development

The risk of inhibitor development negatively impacts the hemophilia treatment market by reducing the effectiveness of standard clotting factor therapies, leading to increased treatment complexity and costs. Patients with inhibitors require alternative, expensive therapies like bypassing agents or gene therapy, limiting market growth. Additionally, managing inhibitors demands frequent monitoring and specialized care, straining healthcare resources. This challenge hinders patient outcomes, discourages treatment adoption, and slows overall market expansion.

Covid-19 Impact

The COVID-19 pandemic disrupted the hemophilia treatment market by delaying diagnoses, reducing hospital visits, and affecting supply chains. Many patients faced difficulties accessing essential therapies due to lockdowns and healthcare system strain. However, the market saw increased adoption of home-based treatments and digital health solutions. As healthcare systems recovered, demand rebounded, driving innovation in gene therapy and extended half-life treatments for improved patient outcomes.

The gene therapy segment is expected to be the largest market share during the forecast period

The gene therapy segment is expected to account for the largest market share during the forecast period because long-term factor production is made possible by advanced therapies such as adeno-associated virus (AAV)-based gene transfer, which enhances patient outcomes and quality of life. The market is expanding more quickly because of more approvals, higher R&D expenditures, and growing demand for curative treatments. Furthermore, gene therapy is becoming more and more popular in the treatment of hemophilia due to its lifetime cost-effectiveness when compared to traditional medicines.

The desmopressin segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the desmopressin segment is predicted to witness the highest growth rate, because desmopressin promotes the release of von Willebrand factor and stored factor VIII; it lowers the risk of bleeding and the frequency of clotting factor infusions. Patient compliance is improved by its simplicity of administration and availability in injectable and intranasal forms. Its demand is further fueled by growing awareness, growing use in emergency situations, and formulation developments, all of which have a favorable impact on the growth of the hemophilia treatment market as a whole.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to growing prevalence of hemophilia, along with favorable reimbursement policies, boosts market growth. Key pharmaceutical advancements, such as extended half-life therapies and recombinant factor products, enhance treatment efficacy. Additionally, government initiatives and research funding support innovation. The presence of major industry players, coupled with patient advocacy groups, further accelerates market expansion. Technological advancements in personalized medicine also contribute to improved treatment outcomes.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, because of easier access to care, especially in developing nations like China and India. Prophylactic treatments are increasingly being used instead of on-demand ones, which is decreasing problems and increasing, demand for gene therapy and factor replacement treatments. The availability of treatments is also being improved by partnerships between pharmaceutical companies and healthcare providers, and the market is expanding due to an older population with inherited bleeding problems.

Key players in the market

Some of the key players profiled in the Hemophilia Treatment Market include Takeda Pharmaceutical Company Limited, Octapharma AG., CSL Behring, Medtronic, Pfizer, Inc., Novo Nordisk A/S., Bayer AG, Allergan, BioMarin, Aptevo Therapeutics, Spark Therapeutics, Inc., AscellaHealth, Sanofi, Baxter International and F. Hoffmann La-Roche Ltd.

Key Developments:

In September 2024, Medtronic expanded aible spine surgery ecosystem with new technologies and Siemens Healthineers partnership, These enhancements are designed to advance AiBLE(TM), the Medtronic smart ecosystem of innovative navigation, robotics, data and AI, imaging, software and implants that enable more predictable outcomes in spine and cranial procedures.

In August 2024, Pfizer Inc. introduced PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.

Hemophilia Types Covered:

  • Hemophilia A
  • Hemophilia B
  • Hemophilia C
  • Acquired Hemophilia
  • Other Hemophilia Types

Treatment Types Covered:

  • Factor Replacement Therapies
  • Desmopressin
  • Gene Therapy
  • Antifibrinolytics
  • Other Treatment Types

Administrations Covered:

  • Intravenous (IV) Administration
  • Subcutaneous (SC) Administration
  • Intramuscular (IM) Administration

End Users Covered:

  • Hospitals
  • Hemophilia Treatment Centers
  • Home Care
  • Ambulatory Surgical Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Hemophilia Treatment Market, By Hemophilia Type

  • 5.1 Introduction
  • 5.2 Hemophilia A
  • 5.3 Hemophilia B
  • 5.4 Hemophilia C
  • 5.5 Acquired Hemophilia
  • 5.6 Other Hemophilia Types

6 Global Hemophilia Treatment Market, By Treatment Type

  • 6.1 Introduction
  • 6.2 Factor Replacement Therapies
    • 6.2.1 Recombinant Factor VIII
    • 6.2.2 Recombinant Factor IX
    • 6.2.3 Plasma-derived Products
    • 6.2.4 Extended Half-life Factor Concentrates
  • 6.3 Desmopressin
  • 6.4 Gene Therapy
  • 6.5 Antifibrinolytics
  • 6.6 Other Treatment Types

7 Global Hemophilia Treatment Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intravenous (IV) Administration
  • 7.3 Subcutaneous (SC) Administration
  • 7.4 Intramuscular (IM) Administration

8 Global Hemophilia Treatment Market, By End User

  • 8.1 Introduction
  • 8.2 Hospitals
  • 8.3 Hemophilia Treatment Centers
  • 8.4 Home Care
  • 8.5 Ambulatory Surgical Centers
  • 8.6 Other End Users

9 Global Hemophilia Treatment Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Takeda Pharmaceutical Company Limited
  • 11.2 Octapharma AG.
  • 11.3 CSL Behring
  • 11.4 Medtronic
  • 11.5 Pfizer, Inc.
  • 11.6 Novo Nordisk A/S.
  • 11.7 Bayer AG
  • 11.8 Allergan
  • 11.9 BioMarin
  • 11.10 Aptevo Therapeutics
  • 11.11 Spark Therapeutics, Inc.
  • 11.12 AscellaHealth
  • 11.13 Sanofi
  • 11.14 Baxter International
  • 11.15 F. Hoffmann La-Roche Ltd.

List of Tables

  • Table 1 Global Hemophilia Treatment Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Hemophilia Treatment Market Outlook, By Hemophilia Type (2022-2030) ($MN)
  • Table 3 Global Hemophilia Treatment Market Outlook, By Hemophilia A (2022-2030) ($MN)
  • Table 4 Global Hemophilia Treatment Market Outlook, By Hemophilia B (2022-2030) ($MN)
  • Table 5 Global Hemophilia Treatment Market Outlook, By Hemophilia C (2022-2030) ($MN)
  • Table 6 Global Hemophilia Treatment Market Outlook, By Acquired Hemophilia (2022-2030) ($MN)
  • Table 7 Global Hemophilia Treatment Market Outlook, By Other Hemophilia Types (2022-2030) ($MN)
  • Table 8 Global Hemophilia Treatment Market Outlook, By Treatment Type (2022-2030) ($MN)
  • Table 9 Global Hemophilia Treatment Market Outlook, By Factor Replacement Therapies (2022-2030) ($MN)
  • Table 10 Global Hemophilia Treatment Market Outlook, By Recombinant Factor VIII (2022-2030) ($MN)
  • Table 11 Global Hemophilia Treatment Market Outlook, By Recombinant Factor IX (2022-2030) ($MN)
  • Table 12 Global Hemophilia Treatment Market Outlook, By Plasma-derived Products (2022-2030) ($MN)
  • Table 13 Global Hemophilia Treatment Market Outlook, By Extended Half-life Factor Concentrates (2022-2030) ($MN)
  • Table 14 Global Hemophilia Treatment Market Outlook, By Desmopressin (2022-2030) ($MN)
  • Table 15 Global Hemophilia Treatment Market Outlook, By Gene Therapy (2022-2030) ($MN)
  • Table 16 Global Hemophilia Treatment Market Outlook, By Antifibrinolytics (2022-2030) ($MN)
  • Table 17 Global Hemophilia Treatment Market Outlook, By Other Treatment Types (2022-2030) ($MN)
  • Table 18 Global Hemophilia Treatment Market Outlook, By Route of Administration (2022-2030) ($MN)
  • Table 19 Global Hemophilia Treatment Market Outlook, By Intravenous (IV) Administration (2022-2030) ($MN)
  • Table 20 Global Hemophilia Treatment Market Outlook, By Subcutaneous (SC) Administration (2022-2030) ($MN)
  • Table 21 Global Hemophilia Treatment Market Outlook, By Intramuscular (IM) Administration (2022-2030) ($MN)
  • Table 22 Global Hemophilia Treatment Market Outlook, By End User (2022-2030) ($MN)
  • Table 23 Global Hemophilia Treatment Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 24 Global Hemophilia Treatment Market Outlook, By Hemophilia Treatment Centers (2022-2030) ($MN)
  • Table 25 Global Hemophilia Treatment Market Outlook, By Home Care (2022-2030) ($MN)
  • Table 26 Global Hemophilia Treatment Market Outlook, By Ambulatory Surgical Centers (2022-2030) ($MN)
  • Table 27 Global Hemophilia Treatment Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.